Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Cash & Equivalents (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed Cash & Equivalents for 6 consecutive years, with $286.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 14.15% to $286.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $286.5 million, a 14.15% decrease, with the full-year FY2025 number at $286.5 million, down 14.15% from a year prior.
  • Cash & Equivalents was $286.5 million for Q4 2025 at PROCEPT BioRobotics, down from $294.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $333.7 million in Q4 2024 to a low of $86.1 million in Q1 2021.
  • A 5-year average of $247.0 million and a median of $263.5 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: surged 230.11% in 2022, then plummeted 44.52% in 2023.
  • PROCEPT BioRobotics' Cash & Equivalents stood at $304.3 million in 2021, then dropped by 27.1% to $221.9 million in 2022, then rose by 15.94% to $257.2 million in 2023, then rose by 29.74% to $333.7 million in 2024, then fell by 14.15% to $286.5 million in 2025.
  • Per Business Quant, the three most recent readings for PRCT's Cash & Equivalents are $286.5 million (Q4 2025), $294.3 million (Q3 2025), and $302.7 million (Q2 2025).